JP2015521182A - 薬物のための眼科用ビヒクルシステム、眼科用キットおよび眼科用組成物の使用 - Google Patents

薬物のための眼科用ビヒクルシステム、眼科用キットおよび眼科用組成物の使用 Download PDF

Info

Publication number
JP2015521182A
JP2015521182A JP2015512029A JP2015512029A JP2015521182A JP 2015521182 A JP2015521182 A JP 2015521182A JP 2015512029 A JP2015512029 A JP 2015512029A JP 2015512029 A JP2015512029 A JP 2015512029A JP 2015521182 A JP2015521182 A JP 2015521182A
Authority
JP
Japan
Prior art keywords
ophthalmic
acid
oil
vehicle system
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015512029A
Other languages
English (en)
Japanese (ja)
Inventor
シュタインフェルト，ウーテ
ホルツァー，フランク
ヒー リー，ハイエック
ヒー リー，ハイエック
マーラー，マルクス
Original Assignee
エフ．ホルツァー ゲゼルシャフト ミット ベシュレンクテル ハフツング
エフ．ホルツァー ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ．ホルツァー ゲゼルシャフト ミット ベシュレンクテル ハフツング, エフ．ホルツァー ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical エフ．ホルツァー ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2015521182A publication Critical patent/JP2015521182A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
JP2015512029A 2012-05-15 2013-05-14 薬物のための眼科用ビヒクルシステム、眼科用キットおよび眼科用組成物の使用 Pending JP2015521182A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12168139.9A EP2664329A1 (de) 2012-05-15 2012-05-15 Ophthalmologisches Vehikelsystem
EP12168139.9 2012-05-15
PCT/EP2013/059927 WO2013171204A2 (de) 2012-05-15 2013-05-14 Ophthalmologisches vehikelsystem für arzneistoffe, ophthalmologisches kit sowie verwendung einer ophthalmologischen zusammensetzung

Publications (1)

Publication Number Publication Date
JP2015521182A true JP2015521182A (ja) 2015-07-27

Family

ID=48463974

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015512029A Pending JP2015521182A (ja) 2012-05-15 2013-05-14 薬物のための眼科用ビヒクルシステム、眼科用キットおよび眼科用組成物の使用

Country Status (12)

Country Link
US (1) US20150139973A1 (enExample)
EP (2) EP2664329A1 (enExample)
JP (1) JP2015521182A (enExample)
KR (1) KR20150014966A (enExample)
CN (1) CN104394859A (enExample)
AU (1) AU2013261873A1 (enExample)
CA (1) CA2873265A1 (enExample)
HK (1) HK1202427A1 (enExample)
IN (1) IN2014DN09594A (enExample)
MX (1) MX2014013884A (enExample)
RU (1) RU2014145440A (enExample)
WO (1) WO2013171204A2 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018079721A1 (ja) * 2016-10-28 2018-05-03 参天製薬株式会社 エピナスチン含有点眼液
JP2018070582A (ja) * 2017-04-24 2018-05-10 参天製薬株式会社 エピナスチン含有点眼液
JP2020059747A (ja) * 2019-12-17 2020-04-16 参天製薬株式会社 エピナスチン含有点眼液
JP2020169213A (ja) * 2020-07-15 2020-10-15 参天製薬株式会社 エピナスチン含有点眼液
WO2022065436A1 (ja) * 2020-09-25 2022-03-31 株式会社イーダーム ドライアイの予防剤，改善剤および治療剤
JP2022541874A (ja) * 2019-06-11 2022-09-28 サイファイ エス．ピー．エー． マイクロエマルション組成物
JP2023508223A (ja) * 2019-12-26 2023-03-01 シェンチェン チェンシン バイオメディシン リサーチ センター カンパニー リミテッド マグノロールとスルフォラファン接合物及びその製造方法
JP2023528633A (ja) * 2020-06-03 2023-07-05 エイザッド ファーマ アクチエンゲゼルシャフト ドライアイ症候群の治療のためのマイクロエマルション

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2666836T3 (es) 2014-06-04 2018-05-08 Alfasigma S.P.A. Formulaciones homogéneas que comprenden ácidos grasos poliinsaturados omega-3 (n-3 PUFA) y resveratrol para administración oral
MX382072B (es) * 2014-06-06 2025-03-12 Archer Daniels Midland Co Microemulsiones y sus usos.
PL3203989T3 (pl) 2014-10-09 2020-06-29 Distretto Tecnologico Sicilia Micro E Nano Sistemi S.C.A.R.L. Nanostrukturalne preparaty do dostarczania sylibininy i innych składników czynnych do leczenia chorób oczu
JP2018510668A (ja) 2015-01-12 2018-04-19 ケダリオン セラピューティックス，インコーポレイテッド 微小液滴の繰り出し装置及び方法
WO2016164830A1 (en) 2015-04-10 2016-10-13 Lagunita Llc Piezoelectric dispenser with replaceable ampoule
KR20180003548A (ko) * 2015-05-12 2018-01-09 라이온 가부시키가이샤 안과용 조성물
EP3128007A1 (en) * 2015-08-07 2017-02-08 Gene Signal International SA Sterile emulsion comprising a stable phosphorothioate oligonucleotide
WO2017025471A1 (en) * 2015-08-07 2017-02-16 Gene Signal International Sa Sterile emulsion comprising a stable phosphorothioate oligonucleotide
ES2846848T3 (es) 2015-10-26 2021-07-29 Harvard College Polisacáridos reducidos y oxidados y métodos de uso de los mismos
WO2018077958A1 (en) 2016-10-27 2018-05-03 Unilever N.V. A personal care composition comprising curcuminoids
CN109906120A (zh) 2017-01-20 2019-06-18 科达莱昂治疗公司 压电流体分配器
US10052343B1 (en) 2017-02-03 2018-08-21 Gene Signal International Sa Sterile formulation comprising a stable phosphorothioate oligonucleotide
CN107158020A (zh) * 2017-05-18 2017-09-15 德施普科技发展温州有限公司 一种眼科用药物组合物及其制备方法
CA3083219A1 (en) 2017-12-08 2019-06-13 Reynaldo Quintana Fluid delivery alignment system
KR102094882B1 (ko) * 2017-12-21 2020-04-28 주식회사 유엠아이옵틱스 항균 누점 플러그 및 그 제조방법
US20210145763A1 (en) * 2018-04-04 2021-05-20 Eye Co Pty Ltd Low thc hemp extract and method of treatment or prevention of an eye disease
US12186234B2 (en) 2018-04-12 2025-01-07 Bausch + Lomb Ireland Limited Topical ocular delivery methods and devices for use in the same
US12350194B1 (en) 2018-04-12 2025-07-08 Bausch + Lomb Ireland Limited Topical ocular delivery of fluids with controlled mass dosing and wireless communication
DE102018208110A1 (de) 2018-05-23 2019-11-28 F. Holzer Gmbh Abgabekopf und Abgabevorrichtung zur dosierten Abgabe flüssiger Präparate sowie Verwendungsmöglichkeiten
AU2019297326B2 (en) 2018-07-03 2025-01-09 Bausch + Lomb Ireland Limited Topical ocular delivery devices and methods for using the same
EP3843721A4 (en) * 2018-08-29 2022-10-12 Ocugen, Inc. OPHTHALMIC COMPOSITIONS AND METHODS OF USE
WO2020070751A1 (en) * 2018-10-03 2020-04-09 Tathagata Dutta Semisolid dosage forms for ophthalmic delivery of antioxidants
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
US12097145B2 (en) 2019-03-06 2024-09-24 Bausch + Lomb Ireland Limited Vented multi-dose ocular fluid delivery system
DE112020002226T5 (de) * 2019-05-03 2022-01-20 Mark Lobanoff Nahinfrarot-Beleuchtung für chirurgische Verfahren
CN110384584A (zh) * 2019-06-28 2019-10-29 四川省一直牛健康管理有限公司 一款中西方芳香植物配伍的功能性眼罩及其制备方法
WO2021049864A1 (ko) * 2019-09-11 2021-03-18 (주) 메드빌 두릅나무 추출물을 함유하는 안구건조증 개선용 조성물
US12496218B1 (en) 2019-11-12 2025-12-16 Bausch + Lomb Ireland Limited Fractionated topical ocular drug delivery methods and devices for use in the same
WO2021183995A1 (en) * 2020-03-13 2021-09-16 Furst-Mcness Company Compositions and methods for prevention and treatment of viral disorders
US12290472B2 (en) 2020-04-17 2025-05-06 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
WO2021212038A1 (en) 2020-04-17 2021-10-21 Kedalion Therapeutics, Inc. Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
CA3180199A1 (en) 2020-04-17 2021-10-21 Yehuda Ivri Hydrodynamically actuated preservative free dispensing system
US20230226002A1 (en) * 2020-06-15 2023-07-20 University Of Utah Research Foundation Retinal bioavailbility of synthetic very-long-chain polyunsaturated fatty acids
WO2022018605A1 (en) * 2020-07-19 2022-01-27 Narayana Nethralaya Foundation A formulation of combination of genistein and calcitriol for management of inflammatory ocular surface conditions
US11033516B1 (en) 2020-09-18 2021-06-15 Spring Discovery, Inc. Combination therapies with disulfiram
IT202000026236A1 (it) * 2020-11-04 2022-05-04 Iromed Group S R L Composizione oftalmica
MA66915A1 (fr) * 2022-01-26 2025-10-31 Amarin Pharmaceuticals Ireland Limited Compositions d'acides gras à libération de lymphe et leurs utilisations pour l'incorporation lymphatique et le traitement de maladies systémiques
CN116253891B (zh) * 2022-08-22 2024-09-20 中南大学湘雅医院 Chta-dsb-da高分子载体及其载药纳米材料的制备和在眼科药物中的应用
KR102513994B1 (ko) * 2022-10-26 2023-03-24 김태윤 반려동물의 눈물 착색예방용 조성물
CN116196263A (zh) * 2023-02-23 2023-06-02 河南大学 一种含有干细胞提取物的护肤组合物及其制备方法
CN118477012B (zh) * 2024-05-07 2025-01-21 广州品域美妆创新科技有限公司 一种含胶原的抗皱紧致组合物及其在化妆品中的应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186333A (ja) * 1991-07-05 1993-07-27 Yissum Res Dev Co Of Hebrew Univ Of Jerusalem 眼用組成物
WO1995005163A1 (en) * 1993-08-13 1995-02-23 Pharmos Corporation Bioadhesive emulsion preparations for enhanced drug delivery
JPH08502759A (ja) * 1993-08-18 1996-03-26 アルコン ラボラトリーズ，インコーポレイテッド 緑内障治療用のエルゴリン誘導体の使用
JP2005529851A (ja) * 2002-03-04 2005-10-06 ノバルティス アクチエンゲゼルシャフト アスコマイシンを含む眼用組成物
JP2009533333A (ja) * 2006-03-31 2009-09-17 ビスタコン・フアーマシユーチカルズ・エルエルシー 眼アレルギーの処置
JP2009544667A (ja) * 2006-07-28 2009-12-17 ノバガリ・フアルマ・エス・エイ 四級アンモニウム化合物を含む組成物
JP2010524992A (ja) * 2007-04-24 2010-07-22 アザト・ファルマ・アーゲー プロスタグランジン類を含有する眼科用水中油型エマルジョン
WO2011113855A2 (en) * 2010-03-17 2011-09-22 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
WO2012059158A1 (de) * 2010-11-05 2012-05-10 F. Holzer Gmbh Zusammensetzung und arzneimittel enthaltend omega-3-fettsäuren sowie einen modulator

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100173876A1 (en) * 2000-12-19 2010-07-08 The Board Of Regents Of The University Of Texas System Oil-based nsaid compositions and methods for making and using same
DE60303235T2 (de) 2003-04-09 2006-09-28 Ursapharm Arzneimittel Gmbh & Co. Kg Fluidspender
US10201548B2 (en) * 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
DE102010023949A1 (de) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186333A (ja) * 1991-07-05 1993-07-27 Yissum Res Dev Co Of Hebrew Univ Of Jerusalem 眼用組成物
WO1995005163A1 (en) * 1993-08-13 1995-02-23 Pharmos Corporation Bioadhesive emulsion preparations for enhanced drug delivery
JPH08502759A (ja) * 1993-08-18 1996-03-26 アルコン ラボラトリーズ，インコーポレイテッド 緑内障治療用のエルゴリン誘導体の使用
JP2005529851A (ja) * 2002-03-04 2005-10-06 ノバルティス アクチエンゲゼルシャフト アスコマイシンを含む眼用組成物
JP2009533333A (ja) * 2006-03-31 2009-09-17 ビスタコン・フアーマシユーチカルズ・エルエルシー 眼アレルギーの処置
JP2009544667A (ja) * 2006-07-28 2009-12-17 ノバガリ・フアルマ・エス・エイ 四級アンモニウム化合物を含む組成物
JP2010524992A (ja) * 2007-04-24 2010-07-22 アザト・ファルマ・アーゲー プロスタグランジン類を含有する眼科用水中油型エマルジョン
WO2011113855A2 (en) * 2010-03-17 2011-09-22 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
WO2012059158A1 (de) * 2010-11-05 2012-05-10 F. Holzer Gmbh Zusammensetzung und arzneimittel enthaltend omega-3-fettsäuren sowie einen modulator

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018079721A1 (ja) * 2016-10-28 2018-05-03 参天製薬株式会社 エピナスチン含有点眼液
JP2018070500A (ja) * 2016-10-28 2018-05-10 参天製薬株式会社 エピナスチン含有点眼液
JP2018070582A (ja) * 2017-04-24 2018-05-10 参天製薬株式会社 エピナスチン含有点眼液
JP2022541874A (ja) * 2019-06-11 2022-09-28 サイファイ エス．ピー．エー． マイクロエマルション組成物
JP7569336B2 (ja) 2019-06-11 2024-10-17 サイファイ エス．ピー．エー． マイクロエマルション組成物
JP2020059747A (ja) * 2019-12-17 2020-04-16 参天製薬株式会社 エピナスチン含有点眼液
JP2023508223A (ja) * 2019-12-26 2023-03-01 シェンチェン チェンシン バイオメディシン リサーチ センター カンパニー リミテッド マグノロールとスルフォラファン接合物及びその製造方法
JP2023528633A (ja) * 2020-06-03 2023-07-05 エイザッド ファーマ アクチエンゲゼルシャフト ドライアイ症候群の治療のためのマイクロエマルション
JP2020169213A (ja) * 2020-07-15 2020-10-15 参天製薬株式会社 エピナスチン含有点眼液
JP2021152068A (ja) * 2020-07-15 2021-09-30 参天製薬株式会社 エピナスチン含有点眼液
JP2022173166A (ja) * 2020-07-15 2022-11-17 参天製薬株式会社 エピナスチン含有点眼液
WO2022065436A1 (ja) * 2020-09-25 2022-03-31 株式会社イーダーム ドライアイの予防剤，改善剤および治療剤

Also Published As

Publication number Publication date
CN104394859A (zh) 2015-03-04
IN2014DN09594A (enExample) 2015-07-31
WO2013171204A3 (de) 2014-01-09
EP2849741A2 (de) 2015-03-25
HK1202427A1 (zh) 2015-10-02
RU2014145440A (ru) 2016-07-10
AU2013261873A1 (en) 2014-12-04
KR20150014966A (ko) 2015-02-09
CA2873265A1 (en) 2013-11-21
EP2664329A1 (de) 2013-11-20
MX2014013884A (es) 2015-06-23
WO2013171204A2 (de) 2013-11-21
US20150139973A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
JP2015521182A (ja) 薬物のための眼科用ビヒクルシステム、眼科用キットおよび眼科用組成物の使用
JP6640919B2 (ja) 半フッ素化アルカン組成物
EP2664330A1 (de) Zusammensetzung und Arzneimittel enthaltend Omega-3-Fettsäuren sowie einen Glucosaminoglucan
WO2012059158A1 (de) Zusammensetzung und arzneimittel enthaltend omega-3-fettsäuren sowie einen modulator
KR20190060787A (ko) 카나비노이드 수용체 결합 리간드를 포함하는 조성물
JP2016193931A (ja) 半フッ化アルカンの混合物を含む組成物
Kinnunen et al. Cationorm shows good tolerability on human HCE-2 corneal epithelial cell cultures
RU2758335C2 (ru) Композиция, способ трансдермальной доставки полиафрона, способ контролируемого высвобождения ингредиента
US20140128475A1 (en) Agent for the prevention, improvement or treatment of retinal disease
JP5358748B1 (ja) ゲラニルゲラニルアセトンを含む眼科用組成物
KR20230158076A (ko) 눈 질환을 치료하기 위한 방법 및 조성물
JP2021523223A (ja) 眼への薬物の非侵襲的な持続型送達のための液体デポー
KR20240109998A (ko) 뇌 및 중추 신경계 질환 치료를 위한 전달 방법
EP4125819A1 (en) Ophthalmic formulation and its use
JP2021523222A (ja) 網膜への薬剤の持続送達のための点眼剤および方法
CN117320714A (zh) 用于治疗眼部疾病的方法和组合物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160324

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170830